ENHANCED PROVIDES CLINICAL TRIAL UPDATE - FIRST OF ITS KIND STUDY CONTINUES WITH ATHLETES HEALTHY & SAFE TO COMPETE
Rhea-AI Summary
Enhanced (NYSE: ENHA) reported an update on its IRB‑approved clinical trial, ASCEND001, now posted on ClinicalTrials.gov and moving into a five‑year observational follow‑up. The 12‑week interventional phase covered 36 of 42 athletes, with aggregate data showing high usage of FDA‑approved performance‑enhancing substances under medical supervision.
According to Enhanced, monitoring to date indicates athletes remain healthy and fit to compete, and the proprietary data will inform personalized protocols on the company’s Live Enhanced consumer platform.
AI-generated analysis. Not financial advice.
Positive
- Interventional phase completed; five-year observational follow-up underway
- 36 of 42 competing athletes enrolled in the clinical study
- Aggregate data: 91% of enrolled athletes used testosterone esters
- Clinical trial data proprietary, positioned as basis of competitive moat
- Study findings to power Live Enhanced personalized consumer protocols
- Early monitoring shows athletes healthy and fit to compete
Negative
- Long-term safety outcomes pending; five-year follow-up still in progress
- Individual athlete protocols remain confidential, limiting external review
News Market Reaction – ENHA
On the day this news was published, ENHA gained 16.50%, reflecting a significant positive market reaction. Argus tracked a peak move of +13.8% during that session. Argus tracked a trough of -6.8% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $309M to the company's valuation, bringing the market cap to $2.18B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
No peers from the stated sector appeared in the momentum scanner, suggesting today’s -6.65% move in ENHA was driven more by company-specific factors than by a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 18 | AI platform partnership | Positive | +4.8% | Multi-million dollar AI partnership for Live Enhanced telehealth platform. |
| May 15 | Distribution partnership | Positive | +12.0% | Rumble named premier partner and official distribution channel for Games. |
| May 14 | Marketing partnership | Positive | +12.0% | Public partnership for co-branded content and VIP fan experiences. |
| May 14 | Event promotion | Neutral | -19.3% | Announcement of Alan Walker-led opening concert for Enhanced Games. |
| May 12 | Major sponsorship deal | Positive | -20.1% | $10 million ZOOP founding partner and creator platform agreement. |
News tied to commercial and partnership expansion has often seen positive price alignment, while some event- and sponsorship-related headlines have coincided with sharp downside moves.
Over the past weeks, Enhanced has focused on building the inaugural Enhanced Games ecosystem and its Live Enhanced platform. Partnership deals with ZOOP (a $10 million agreement on May 12), Public, and Rezolve Ai aimed to expand distribution, creator engagement, and AI capabilities. A content agreement with Rumble and an opening concert announcement further highlighted event build-out. Market reactions have been mixed: some partnership news produced double-digit gains, while other event-related headlines saw declines, underscoring volatile sentiment around the business model.
Market Pulse Summary
The stock surged +16.5% in the session following this news. A strong positive reaction aligns with how some prior strategic announcements around partnerships and platform build-out led to gains for ENHA. However, past news flow also showed sharp pullbacks after seemingly constructive headlines. Investors would likely weigh this clinical update’s emphasis on safety, long-term follow-up of up to five years, and proprietary data against existing volatility patterns and execution risk around monetizing the Live Enhanced platform.
Key Terms
institutional review board regulatory
clinicaltrials.gov regulatory
interventional phase medical
erythropoietin (epo) medical
anabolic steroid medical
biomarker analysis medical
data and safety monitoring board regulatory
principal investigators medical
AI-generated analysis. Not financial advice.
Enhanced Releases Aggregate Substance Usage Data Ahead of Competition With Study Now Available for Review on Clinicaltrials.org
The trial can be located on ClinicalTrials.gov by typing the study acronym "ASCEND001" into the 'other terms' search bar on the homepage. Alternatively, viewers can enter the study's title "Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes" as a search cue.
ENHANCED PROVIDES AGGREGATE SUBSTANCE USAGE DATA AHEAD OF GAMES
With the inaugural Enhanced Games fast approaching on Sunday May 24th (8:30pm EDT/5:30pm PDT) in
The clinical trial encompassed 36 of the 42 athletes competing. Of those 36 athletes, 2 are competing naturally. Six athletes did not participate in the study with two of those six competing naturally. Athletes participating in the study were permitted to consider substances across five approved categories, including testosterone esters, anabolic agents, peptides and growth factors, metabolic modulators, and stimulants. Only legal substances under
91% of athletes used testosterone or testosterone esters79% of athletes used human growth hormone (hGH)62% of athletes used stimulants (eg. Adderall)50% of athletes used metabolic modulators, primarily ancillary compounds (eg. Anastrozole) which was used alongside anabolic agents to support protocols41% of athletes used erythropoietin (EPO)29% of athletes used an anabolic steroid agent (eg. Deca durabolin)5% of athletes used hormonal support therapies (eg. hCG)
"We are encouraged to share that our clinical trial is now open for review with some of the preliminary aggregate totals from the study ahead of the Games," said Dr. Guido Pieles, Chair of Enhanced's Independent Medical Commission and Independent Scientific Commission. "We have been regularly assessing the athletes throughout the study period and we're very pleased with the results and the overall health picture each participating athlete has demonstrated during the study."
The clinical data generated through this study is proprietary to Enhanced and forms the foundation of the company's competitive moat. No other consumer health platform in the world is designing personalized enhancement protocols informed by IRB-approved elite athlete research. Through the Live Enhanced platform, learnings from elite performance environments will flow directly into individualized consumer protocols, continuously improving product recommendations and personalizing the experience at scale. What works for a world record holder informs what works for consumers.
Enhanced Medical Program Overview
The primary objective of the study is to assess the safety and tolerability of certain approved medical compounds when administered to adult athletes under individualized medical supervision over a treatment period of up to 25 weeks. Primary endpoints include the incidence of treatment-related adverse events and the proportion of participants who discontinue use due to such events. Secondary objectives include evaluating changes in physiological and performance-related parameters through structured baseline and follow-up assessments. Assessments include cardiology evaluation and imaging, respiratory testing, organ health imaging, body composition analysis, musculoskeletal assessment, neurocognitive screening and biomarker analysis using blood, urine and saliva samples.
All participants underwent comprehensive baseline assessments, ongoing medical monitoring during the treatment period, and will receive structured long-term follow-up for up to five years to assess health outcomes. All substances used in the study were approved by relevant health authorities and were procured through regulated pharmaceutical supply chains. Administration, dosages, adjustment, interruption, or discontinuation of any substance were determined by the Principal Investigators based on individualized medical evaluation and in accordance with IRB-approved protocols in collaboration with the independent medical and science commission. Participants participated with full consent and may decline or discontinue participation at any time. The study is sponsored by Enhanced. Clinical oversight and decision-making are the responsibility of the Principal Investigators and were subject to independent monitoring mechanisms, including a Data and Safety Monitoring Board.
"We are very encouraged by the early findings, which indicate excellent progress toward achieving the study's objectives," said Maximilian Martin, CEO of Enhanced. "We are particularly encouraged by the initial impacts the protocols appear to have had on athlete recovery and injury prevention."
About Enhanced Group, Inc.
Enhanced Group, Inc. (NYSE: ENHA) is an elite sports competition and performance products company committed to giving athletes and people alike access to products that optimize their health, performance and recovery. The Live Enhanced platform provides consumers access to products, and protocols that optimize health, longevity and vitality. As a premium brand, Enhanced aims to revolutionize and lead the Performance Medicine category. For more information about mission of Enhanced please visit www.enhanced.com
About The Enhanced Games
The Enhanced Games will champion scientific innovation and integrity in elite sporting competition. Enhanced believes in an objective, evidence-based approach to competition, one that celebrates athletic excellence and unlocks athletes' full potential. The Enhanced Games is not only creating a sporting event that is thrilling for spectators but also a beacon for scientific transparency and athlete welfare. By putting athletes first, it gives them the opportunity to reach their full potential and be compensated accordingly, all while ensuring their safety through rigorous medical supervision and scientific oversight. The inaugural Enhanced Games will take place on May 24, 2026 and will be held at a purpose-built competition complex at Resorts World Las Vegas. The Games will offer unprecedented financial incentives to athletes.
Contact
Chris Jones
Chief Communications Officer, Enhanced Group, Inc.
Asia Gilbert
Head of Investor Relations, Enhanced Group, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enhanced-provides-clinical-trial-update--first-of-its-kind-study-continues-with-athletes-healthy--safe-to-compete-302778243.html
SOURCE Enhanced